This article is more than 5 years old. Information may no longer be current.

VIDEO: Novaliq announces full enrollment in phase 2 trial of dry eye treatment

Issue: May 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW ORLEANS — At the Ophthalmology Innovation Summit, Bernhard Günther, CEO of Novaliq, gives an update on the company portfolio, including news that it had completed enrollment in a phase 2 study of CyclASol for the treatment of moderate to severe dry eye disease.